Ltr Pharma Limited · ASX:LTP
Ltr Pharma — Bell Potter Healthcare Conference 2025
14 slides from Ltr Pharma's conference presentation, Nov 19, 2025
Slide 1: Lead nasal spray portfolio
For personal use only Lead nasal spray portfolio Bell Potter Healthcare Conference 1 November 2025
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer ‣ Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd ‣ Forward looking statements: This presentation contains forward-looking information about the (Company or LTP) to provide general information about the Company. The information in th
Slide 3: Executive Summary
Executive Summary Rapidly commercialising SPONTAN® and ROXUS® LTR Pharma First-in-class rapid, on-demand nasal spray treatments For personal use only for Erectile Dysfunction (ED) Late-Stage Pharmaceutical Platform with Validated Early Market Access SPONTAN Now available under TGA's Special Access S
Slide 4: Investment Highlights
Investment Highlights LTR Pharma positioned in a clear gap in the market For personal use only Multiple path Compelling pivotal Blockbuster Blue chip Multiple upcoming to market pharmacokinetic market with issues partners milestones study data ‣ SPONTAN® active ‣ 5x faster absorption than ‣ Existing
Slide 5: Understanding the Market Need
Understanding Physical causes Psychological Impact the Market Need ‣ Heart health ‣ Relationship problems A significant healthcare ‣ Hormone balance ‣ Mental wellbeing For personal use only challenge affecting ‣ Prostate Cancer ‣ Day to day stress relationships and ‣ Diabetes quality of life ‣ Medic
Slide 6: Prevalence In Key Markets
Prevalence In Key Markets As risk factors become more prevalent, so does ED Global ~322m men by 2025 For personal use only USA China Aus EU 60.7% ~30m ~33m ~150m of males 45y/o+ Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023 Bell Potter HCC | November 20
Slide 7: Current Treatments
Current Treatments Oral PDE5 inhibitors & SPONTAN® Nasal Spray Oral Phosphodiesterase-5 (PDE5) Issues with oral For personal use only inhibitors are first-line treatments PDE5 inhibitors Product Main Time before sexual Approval Generic Does not work Brand(s) activity for dose Date (US) availability
Slide 8: Nasal Administration
Nasal Administration Delivery mechanism can solve many of issues facing PDE5 inhibitors For personal use only Advantages vs oral administration Less active More rapid pharmaceutical onset of action ingredients required Higher rate of absorption Less drug degradation due to bypassing the digestive sy
Slide 9: SPONTAN Pivotal Pharmacokinetic Study
SPONTAN® Pivotal Pharmacokinetic Study Rapid onset effect, consistent delivery and improved safety profile For personal use only ‣ SPONTAN® nasal spray achieved rapid absorption and Parameter Vardenafil faster onset of action compared to oral PDE5 inhibitors. (5mg) (10mg) oral ‣ SPONTAN® delivered s
Slide 10: In-Market NOW
In-Market NOW Commercial Platform Active: Growing Prescriber Network ‣ RHC – experts in treating ED and early adopters of SPONTAN For personal use only 1. JV with Restorative ‣ Online bookings, consults, men’s health education, telehealth Health Clinic (RHC) solutions and prescribing SPONTAN on ‣ ht
Slide 11: US Commercialisation
US Commercialisation Multiple Active Routes to Market ROXUS > Early Market Entry via Personalised Medicine For personal use only ‣ ROXUS to be available via 503(a) personalised medicine pathway ‣ Market entry with 1st sales targeted for H1 CY2026 ‣ Focus on urology/men’s health prescribers and teleh
Slide 12: 2025-2026 Key Milestones
2025-2026 Key Milestones For personal use only Calendar Year Q1 2026 H1 2026 2026 Phase II Clinical Study enrolment 1st US Sales Published data ROXUS Development Completed Phase II completion and data read out OROFLOW development Human factor study completion Partnerships discussions Animal Toxicolo
Slide 13: Growing Pipeline of Novel Nasal Spray Treatments
Growing Pipeline of Novel Nasal Spray Treatments Validated Platform Supporting Multiple Indications Indication/ Pre-clinical Proof of Phase 1 Phase 2 Phase 3 For personal use only Program Concept (PK study) (PK study) Erectile Dysfunction (ED) / TGA early access Available now / FDA 503(a) Personalis
Slide 14: Corporate Structure
Corporate Structure ASX Code LTP For personal use only Shares on issue 181.61M Market Capitalisation A$79.91M Contact investors@ltrpharma.com Cash and cash equivalents (30 June 2025) A$31.84M www.ltrpharma.com Top 20 shareholder percentage 43.22% As of 7 November 2025 Authorised for release by the B